Tigecycline: First of a New Class of Antimicrobial Agents

@article{Rose2006TigecyclineFO,
  title={Tigecycline: First of a New Class of Antimicrobial Agents},
  author={Warren E. Rose and Michael Joseph Rybak},
  journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year={2006},
  volume={26}
}
  • W. Rose, M. Rybak
  • Published 1 August 2006
  • Medicine
  • Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Tigecycline is the first commercially available member of the glycylcyclines, a new class of antimicrobial agents. The glycylcyclines are derivatives of the tetracycline antibiotics, with structural modifications that allow for potent gram‐positive, gram‐negative, and anaerobic activity, including certain multidrug‐resistant strains. The enhanced activity can be attributed to stronger binding affinity and enhanced protection against several mechanisms of resistance that affect other antibiotic… Expand
Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review
  • S. Yaghoubi, A. Zekiy, +5 authors Farajolah Maleki
  • Medicine
  • European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
  • 2021
TLDR
Tigecycline showed in vitro susceptibility to Coxiella spp, Rickettsia spp. Expand
Development of Tyrocidine A analogues with improved antibacterial activity.
TLDR
Examination of the structure- activity relationship between the analogues demonstrated a preference for increased amphipathicity but did not show a clear preference for increasing hydrophilicity versus hydrophobicity in improving antibacterial activity, but movement of positively charged lysine residues or neutral pentafluorophenyl residues to different positions within the cyclopeptide ring system demonstrated improvements in antibacterialactivity. Expand
Review of Tigecycline: Focus on Clinical Utilization
TLDR
The antimicrobial profile and available clinical data for the first member of the glycylcycline class, tigecycline, may provide a therapeutic option in select patients, given its broad spectrum of activity, including multi-drug resistant (MDR) strains. Expand
Role of Combination Antimicrobial Therapy for Vancomycin‐Resistant Enterococcus faecium Infections: Review of the Current Evidence
TLDR
The mechanisms of action and resistance to currently available anti‐VRE antimicrobial agents including newer agents such as oritavancin and dalbavancins will be presented and novel combination therapies including β‐lactams and fosfomycin, and the promising results from in vitro, animal studies, and clinical experience in the treatment of VRE faecium will be discussed. Expand
In vitro activity of tigecycline as a therapeutic option against multidrug-resistant Acinetobacter spp.
TLDR
Tigecycline has been shown to have potent in vitro activity against MDR Acinetobacter spp. Expand
Combination therapy for carbapenem-resistant Gram-negative bacteria
TLDR
Clinical evidence of the major drugs utilized in combination schemes and how they should be prescribed considering pharmacokinetic/pharmacodynamic characteristics against CR GNB will be reviewed in this article. Expand
Burden of extensively drug-resistant and pandrug-resistant Gram-negative bacteria at a tertiary-care centre
TLDR
The findings of this study reveal increased burden of XDR and PDR Gram-negative bacteria in a tertiary-care centre and highlights the widespread dissemination of these bacteria in the community. Expand
In vitro activity of tigecycline against methicillin-resistant Staphylococcus aureus, including livestock-associated strains
TLDR
Tigecycline showed good activity against MRSA strains in vitro, and this discrepancy warrants further investigations into the preferred test conditions for tigecYcline. Expand
Emerging New Therapeutics Against Key Gram-Negative Pathogens
Publisher Summary This chapter focuses on compounds in late preclinical and clinical development and compounds derived from known and new classes of antibiotics that show promising activity againstExpand
Non-antimicrobial strategies for the prevention and treatment of infections by multidrug-resistant gram-negative bacilli
TLDR
In vivo, AOA-2 in combination with colistin reduced bacterial spleen and lung loads, bacteremia and mortality rates, in comparison with the monotherapy with colistsin, and in vivo, the therapeutic efficacy of Aoa-2 against A. baumannii and P. aeruginosa in experimental murine models of peritoneal sepsis and pneumonia was evaluated. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 83 REFERENCES
In vitro activity of tigecycline (GAR-936), a novel glycylcycline, against vancomycin-resistant enterococci and staphylococci with diminished susceptibility to glycopeptides.
TLDR
This study compared the in vitro activity of tigecycline with that of tetracycline, vancomycin and teicoplanin against 157 unrelated, non-duplicate clinical isolates obtained in the microbiology laboratory during 1998–2001. Expand
Preclinical Pharmacology of GAR‐936, a Novel Glycylcycline Antibacterial Agent
  • S. Projan
  • Biology, Medicine
  • Pharmacotherapy
  • 2000
TLDR
It is most significant that GAR‐936 and other glycylcyclines are active against bacterial strains carrying either or both of the two major forms of tetracycline resistance: efflux and ribosomal protection. Expand
Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
TLDR
Tigecycline spectrum and potency were evaluated against a global collection of pathogens recovered from community-acquired respiratory infections or from hospitalized patients with pneumonia, showing potent activity against many of Gram-positive, Gram-negative, atypical, and anaerobic organisms. Expand
Antimicrobial activity of tigecycline (GAR-936) tested against 3498 recent isolates of Staphylococcus aureus recovered from nosocomial and community-acquired infections.
Tigecycline is a novel 9-t-butylglycylamido derivative of minocycline that has demonstrated activity against a variety of Gram-positive and -negative bacterial pathogens. In vitro activity ofExpand
In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens
TLDR
The data suggest that tigecycline and daptomycin may offer therapeutic options against clinically relevant resistant pathogens for which current alternatives for treatment are limited. Expand
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
  • A. Gales, R. Jones
  • Biology, Medicine
  • Diagnostic microbiology and infectious disease
  • 2000
TLDR
GAR- 936 has potent in vitro activity against a wide range of clinically important pathogenic bacteria, and that several gram-positive and -negative isolates resistant to older tetracyclines and other drug classes remain susceptible to GAR-936, the newest glycylcycline candidate for clinical use. Expand
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004)
TLDR
Tigecycline appears to be a promising new glycylcycline agent for the treatment of many types of pathogens with varying resistance phenotypes. Expand
In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
TLDR
Tigecycline appears to be a promising new glycylcycline agent for the treatment of many types of pathogens with varying resistance phenotypes. Expand
In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
TLDR
It is confirmed that tigecycline maintains a truly broad spectrum like the tetracycline class while enhancing potency, making it an attractive candidate for continued clinical development against pathogens causing serious community-acquired respiratory tract infections, as well as cutaneous infections. Expand
In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
TLDR
The excellent expanded broad-spectrum activity of tigecycline demonstrated in vitro against clinical isolates confirmed its potential utility for pathogens associated with complicated skin and skin-structure infections or complicated intra-abdominal infections. Expand
...
1
2
3
4
5
...